BR112013009660A8 - Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante - Google Patents

Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante

Info

Publication number
BR112013009660A8
BR112013009660A8 BR112013009660A BR112013009660A BR112013009660A8 BR 112013009660 A8 BR112013009660 A8 BR 112013009660A8 BR 112013009660 A BR112013009660 A BR 112013009660A BR 112013009660 A BR112013009660 A BR 112013009660A BR 112013009660 A8 BR112013009660 A8 BR 112013009660A8
Authority
BR
Brazil
Prior art keywords
fusion protein
dna sequence
recombinant vector
activity factor
fix
Prior art date
Application number
BR112013009660A
Other languages
English (en)
Other versions
BR112013009660A2 (pt
BR112013009660B1 (pt
Inventor
Sun Lee Min
Kim Hun-Taek
Lee Bong-Yong
Hoon Park Mahn
Jung Lim Yun
Original Assignee
Sk Chemicals Co Ltd
Tiumbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd, Tiumbio Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of BR112013009660A2 publication Critical patent/BR112013009660A2/pt
Publication of BR112013009660A8 publication Critical patent/BR112013009660A8/pt
Publication of BR112013009660B1 publication Critical patent/BR112013009660B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROTEÍNA DE FUSÃO COM FATOR DE ATIVIDADE IX. É revelada uma proteína de fusão que compreende o fator de coagulação sanguíneo IX (FIX) e transferrina. A proteína de fusão apresenta aprimorada atividade específica do FIX, em comparação ao FIX natural, e pode ser útil no tratamento de doenças associadas com a deficiência do FIX.
BR112013009660-8A 2010-10-20 2011-10-19 Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante BR112013009660B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0102572 2010-10-20
KR20100102572 2010-10-20
PCT/KR2011/007795 WO2012053823A2 (ko) 2010-10-20 2011-10-19 인자 ix 활성을 갖는 융합 단백질

Publications (3)

Publication Number Publication Date
BR112013009660A2 BR112013009660A2 (pt) 2016-07-12
BR112013009660A8 true BR112013009660A8 (pt) 2017-10-10
BR112013009660B1 BR112013009660B1 (pt) 2023-01-10

Family

ID=45975731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009660-8A BR112013009660B1 (pt) 2010-10-20 2011-10-19 Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante

Country Status (9)

Country Link
US (1) US9617328B2 (pt)
EP (1) EP2631249B1 (pt)
JP (1) JP6177130B2 (pt)
KR (1) KR101853405B1 (pt)
CN (2) CN106905433A (pt)
BR (1) BR112013009660B1 (pt)
CA (3) CA2942087C (pt)
ES (1) ES2676549T3 (pt)
WO (1) WO2012053823A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294857B (zh) * 2014-06-18 2019-02-19 上海交通大学 基于fix的抗原表位及其应用
CA2989116A1 (en) * 2015-06-12 2016-12-15 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
US11820807B2 (en) * 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
MX2018000307A (es) 2015-06-23 2018-05-02 Childrens Hospital Philadelphia Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
WO2017070167A1 (en) * 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
US20210155674A1 (en) * 2017-06-30 2021-05-27 Western University Of Health Sciences Factor ix-transferrin fusion proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CN101519449A (zh) * 2001-08-30 2009-09-02 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
KR20040059490A (ko) * 2001-08-30 2004-07-05 바이오렉시스 파마슈티칼 코포레이션 변형 트랜스페린 융합 단백질
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
EP3552627A1 (en) * 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
LT2004683T (lt) * 2006-03-24 2016-10-10 Biogen Hemophilia Inc. Pc5, kaip faktoriaus ix pro-peptidą apdorojantis fermentas
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
JP2008232916A (ja) * 2007-03-22 2008-10-02 Canon Inc 標的物質検出キット

Also Published As

Publication number Publication date
CA2814947A1 (en) 2012-04-26
WO2012053823A3 (ko) 2012-07-26
US20130296534A1 (en) 2013-11-07
EP2631249B1 (en) 2018-05-16
CA2942087C (en) 2018-07-24
KR101853405B1 (ko) 2018-05-02
WO2012053823A2 (ko) 2012-04-26
BR112013009660A2 (pt) 2016-07-12
EP2631249A2 (en) 2013-08-28
US9617328B2 (en) 2017-04-11
EP2631249A4 (en) 2014-12-03
CA2981467A1 (en) 2012-04-26
ES2676549T3 (es) 2018-07-20
KR20120047771A (ko) 2012-05-14
CA2981467C (en) 2018-07-24
CA2814947C (en) 2018-07-10
JP6177130B2 (ja) 2017-08-09
JP2013544506A (ja) 2013-12-19
WO2012053823A9 (ko) 2012-10-04
CA2942087A1 (en) 2012-04-26
CN103180344A (zh) 2013-06-26
BR112013009660B1 (pt) 2023-01-10
CN106905433A (zh) 2017-06-30

Similar Documents

Publication Publication Date Title
BR112013009660A8 (pt) Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
EA201301350A1 (ru) Модифицированные полипептиды фактора vii и их применение
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
MX2011013126A (es) Alimentos medicos con glicomacropeptido para el manejo nutricional de fenilcetonuria y otros trastornos metabolicos.
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
BR112015021869A2 (pt) Domínios gla como agentes alvo
IN2012DN00908A (pt)
NZ702169A (en) The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome
NZ602317A (en) Stabilized alpha-galactosidase and uses thereof
MX348567B (es) Proteina de fusion que tiene actividad de factor vii.
SMT201500132B (it) Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
EA201992135A1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2015001508A (es) El uso de antitrombina en la oxigenacion por membrana extracorporea.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
BR112015019197A2 (pt) tratamento de doença de enxerto versus hospedeiro em pacientes transplantados

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TIUMBIO CO., LTD (KR)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/10/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.